Writing for the Wall Street Journal’s opinion page, Allysia Finley explains that while randomized controlled trials can yield important insights, it is a medical mistake and a disservice to patients to dismiss other types of evidence. Very relevant in the context of COVID-19 treatments, especially hydroxychloroquine.
“Some experts have dismissed the antimalarial hydroxychloroquine, or HCQ, even though more than a dozen observational studies have found it beneficial. A retrospective observational study of Covid-infected nursing-home residents in France, for instance, found those treated with HCQ and azithromycin were 40% less likely to die.”
Read the whole thing here.